This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
VISIONARY-MS was a randomized, quadruple-masked, phase 2 parallel-group treatment trial evaluating CNM-Au8 in participants with multiple sclerosis and chronic optic neuropathy.
| Feature | VISIONARY-MS |
|---|---|
| Clinical trial identifier | NCT03536559 |
| Title | Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis |
| Status | TERMINATED |
| Start date | 2018-11-23 |
| Primary completion date | 2022-04-27 |
| Lead sponsor | Clene Nanomedicine |
| Allocation | Randomized |
| Masking | Quadruple |
2. Clinical Question
Population
Participants with relapsing remitting multiple sclerosis, optic neuropathy, optic neuritis, and demyelination.
Intervention
CNM-Au8.
Comparator
Placebo.
Primary question
Does CNM-Au8 affect visual function measured by change in BC-LCLA score from baseline to Week 48?
3. Trial Design
73 participants
3 arms
Blinded assessment
Visual function endpoint
Treatment.
CNM-Au8 (drug); placebo (drug).
4. Primary Endpoint
| Endpoint | Definition | Time frame |
|---|---|---|
| Measures of Visual Function | Change in Best-Corrected Low-Contrast Letter Acuity (BC-LCLA) score: Mean change in BC-LCLA from Baseline to Week 48 in the most affected eye as measured by 2.5% low contrast Sloan letter charts. | Baseline to 48 weeks |
5. Planned Analysis
The registry identifies the primary visual-function endpoint as a mean change in BC-LCLA score from baseline to Week 48. For a continuous outcome measured as change from baseline, statistical analysis commonly focuses on comparing mean changes between randomized groups, often using models that account for baseline measurements and treatment assignment.
The ClinicalTrials.gov record does not report posted statistical analyses or results for the primary endpoint.
6. Statistical Methodology
Continuous endpoint analysis
BC-LCLA is a quantitative visual-function measure. A comparison of mean change evaluates whether average improvement or decline differs between randomized groups over the specified follow-up period.
Randomization and masking
Randomization helps balance measured and unmeasured baseline characteristics between groups. Quadruple masking reduces the potential influence of treatment expectations on participants, investigators, and outcome assessment.
7. Statistical Methods Explained
Why measure change from baseline?
Change scores evaluate how a participant's outcome differs after treatment compared with their own starting value. This can reduce variability caused by differences in baseline measurements.
Why is BC-LCLA useful as a statistical endpoint?
A standardized quantitative visual-function measure allows investigators to compare average changes between randomized treatment groups.
What does a mean change estimate represent?
A mean change summarizes the average movement in the outcome across participants. It does not describe every individual's response.
Why does randomization matter?
Randomization creates the basis for comparing groups because treatment assignment is determined independently of participant characteristics.
Why is masking important?
Masking can reduce bias in subjective experiences, clinical assessments, and interpretation of outcomes.
8. Limitations
- No posted statistical analyses: The ClinicalTrials.gov record does not report formal statistical analyses or estimates for the primary endpoint.
- Sample size: Enrollment was 73 participants, which may limit precision for treatment-effect estimates.
- Endpoint specificity: BC-LCLA measures a particular aspect of visual function and does not represent all aspects of multiple sclerosis disease activity.
- Registry completeness: The public registry record does not provide additional efficacy analyses, subgroup analyses, safety summaries by arm, or missing-data methodology.
9. Why This Trial Matters Statistically
VISIONARY-MS illustrates several important concepts in clinical trial methodology: randomized treatment comparison, masked outcome assessment, continuous endpoints, and interpretation of registry-reported endpoints.
| Concept | How it appears in VISIONARY-MS |
|---|---|
| Randomization | Randomized allocation of participants |
| Masking | Quadruple-masked design |
| Parallel design | Three-arm parallel treatment structure |
| Continuous outcome | Mean change in BC-LCLA score |
| Follow-up window | Baseline to Week 48 assessment |
10. Sources
- ClinicalTrials.gov record: VISIONARY-MS (NCT03536559)